San Diego, CA - April 14, 2020 - Crown Bioscience has announced the appointment of Jean-Pierre Wery, PhD as executive chairman of the board effective immediately. Dr. Wery will also serve as chief technology officer (CTO) for JSR Life Sciences, LLC.
SUNNYVALE, CA – Mar. 14, 2019 – JSR announced today that it will establish a US headquarters for its biotechnology and life sciences focused businesses under the name JSR Life Sciences, LLC effective April 1, 2019. The formation of JSR Life Sciences will centralize leadership and resources to support the company’s value proposition of driving innovation to provide a portfolio of integrated products, services and technologies to help partners develop and commercialize therapeutics and diagnostics that benefit global human health.
Vancouver, Canada - September 18, 2018 - Aspect Biosystems, a privately held biotechnology company focused on commercializing cutting-edge bioprinting technologies, is pleased to announce a new collaboration to develop human liver tissue with JSR Corporation, a leading materials supplier in a variety of technology driven markets. Through this collaboration, Aspect’s proprietary Lab-on-a-Printer™ 3D bioprinting platform and JSR’s advanced materials technology will be used to develop vascularized human liver lobules.
Oxford Performance Materials and JSR Corporation Announce Partnership to Advance OPM Technology Platform Throughout Asia
SOUTH WINDSOR, Conn. and TOKYO - May 14, 2018 - Oxford Performance Materials, Inc. (OPM), a leader in advanced materials science and high performance additive manufacturing (HPAM®), and Tokyo-based JSR Corporation (JSR), a leading materials supplier in a variety of technology driven markets, today announced a partnership to advance OPM’s poly-ether-ketone-ketone (PEKK)-based 3D-printed orthopedic devices and biomedical & dental materials businesses throughout Asia.
TOKYO – Dec. 20, 2017 – JSR Life Sciences (JLS) announced today that JSR Corporation has agreed to purchase Crown Bioscience International (TPEx: ticker 6554) at 12 Billion New Taiwan Dollar, a global drug discovery and development services company providing translational platforms to advanced oncology, inflammation, cardiovascular and metabolic disease research. This acquisition marks JSR’s largest life sciences-focused investment to date, extending the company’s portfolio to include industry-leading contract research and development capabilities